Nasdaq · Healthcare
Evolus, Inc. (EOLS)
As-reported financials and recent SEC filings for Evolus, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$297.2M
Net income
$-51.6M
Net margin
-17.4%
Diluted EPS
$-0.80
ROE
223.5%
P/E (TTM)
—
Market cap
$469.5M
Debt / equity
-6.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $297.2M | $266.3M | $202.1M | $148.6M | $99.7M |
| Gross profit | $197.1M | $182.3M | $137.6M | $89.8M | $56.1M |
| Operating income | $-32.7M | $-34.4M | $-49.2M | $-65.3M | $-44.4M |
| Net income | $-51.6M | $-50.4M | $-61.7M | $-74.4M | $-46.8M |
| Diluted EPS | $-0.80 | $-0.81 | $-1.08 | $-1.33 | $-0.94 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
EFFECT2026-06-12
View on EDGAR →8-K2026-06-12
View on EDGAR →S-32026-06-05
View on EDGAR →10-Q2026-05-04
View on EDGAR →8-K2026-05-04
View on EDGAR →DEFA14A2026-04-29
View on EDGAR →DEF 14A2026-04-29
View on EDGAR →ARS2026-04-29
View on EDGAR →Go deeper on EOLS
Search Evolus, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.